Effective
2001 and later
Reportable
for cases diagnosed
2001 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
The acute myeloid leukemias with related precursor neoplasms are characterized by recurrent genetic abnormalities of prognostic significance. This specific neoplasm is an acute myeloid leukemia with abnormal marrow eosinophils.
In addition to the usual morphological features of acute myelomonocytic leukemia, the BM shows a variable number of eosinophils (usually increased but sometimes less than five percent). The most striking abnormalities include the immature eosinophilic granules, usually present at later stages.
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10
In addition to the usual morphological features of acute myelomonocytic leukemia, the BM shows a variable number of eosinophils (usually increased but sometimes less than five percent). The most striking abnormalities include the immature eosinophilic granules, usually present at later stages.
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10
Diagnostic Confirmation
This AML is part of the "AML with recurrent genetic abnormalities" group. Since this AML is diagnosed based on genetics, diagnostic confirmation will always be 3.
Grade
Not Applicable
Module Rule
See abstractor notes
Alternate Names
Definition
Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) resulting in CBFB-MYH11 is an AML that usually shows monocytic and granulocytic differentiation and characteristically an abnormal eosinophil component in the bone marrow.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Immunophenotyping
Genetics Data
CBFB at 16q22 to MYH11 at 16p13.1 fusion
CBFB-MYH11
inv(16)(p13.1q22)
t(16;16)(p13.1;q22)
Immunophenotyping
CD4+ (expression/positive) monocytic
CD11b+ (expression/positive) monocytic
CD11c+ (expression/positive) monocytic
CD13+ (expression/positive) granulocytic
CD14+ (expression/positive) monocytic
CD15+ (expression/positive) granulocytic
CD33+ (expression/positive) granulocytic
CD36+ (expression/positive) monocytic
CD64+ (expression/positive) monocytic
CD65+ (expression/positive) granulocytic
Lysozyme+ (expression/positive) monocytic
MPO+ (expression/positive) granulocytic
Treatments
Chemotherapy
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Bone marrow aspiration and biopsy
CT (CAT) scan
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Peripheral blood smear
Physical exam and history
Progression and Transformation
Longer complete remissions when treated with high dose cytarabine in the consolidation phase
Older patients and those with KIT mutations have higher risk of relapse and worse survival
Epidemiology and Mortality
Age: predominantly younger patients
Survival: longer complete remissions possible when treated with high dose cytarabine in the consolidation phase
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 132-134
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 132-134
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq